Telomir Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
TELO$0.69-2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $4,515,704 | $7,286,670 |
| Prepaid expenses | 125,641 | 54,691 |
| Total current assets | 4,641,345 | 7,341,361 |
| Total assets | $4,641,345 | $7,341,361 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable and accrued liabilities | $167,990 | $536,769 |
| Due to officer | — | 155,518 |
| Accrued compensation - officer | — | 417,470 |
| Insurance loan payable | 68,756 | — |
| Due to related parties | — | 318,234 |
| Total current liabilities | 236,746 | 1,427,991 |
| Total liabilities | 236,746 | 1,427,991 |
| Commitments and contingencies (Note 9) | - | |
| Stockholders’ Equity: | ||
| Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. | — | — |
| Common Stock, no par value; 300,000,000 shares authorized, 68,774,956 and 34,380,971 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 48,832,362 | 46,923,433 |
| Accumulated deficit | (44,427,763) | (41,010,063) |
| Total stockholders’ equity | 4,404,599 | 5,913,370 |
| Total liabilities and stockholders’ equity | $4,641,345 | $7,341,361 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.